OTCPK:YBGJ (China)
Â
Ordinary Shares - Class A
$
1.17
0 (0%)
01:14 PM EST
Current and historical daily PE Ratio for Yubo International Biotech Ltd (
) from 2021 to Jun 25 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Yubo International Biotech stock (YBGJ) PE ratio as of Jun 25 2024 is 0.
More Details
Yubo International Biotech Ltd (YBGJ) PE Ratio (TTM) Chart
Yubo International Biotech Ltd (YBGJ) PE Ratio (TTM) Historical Data
View and export this data going back to 2021. Start your Free Trial
Total 713
- 1
- 2
- 3
- 4
- 5
- 6
- 8
| Yubo International Biotech PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-25 | At Loss | 2024-04-19 | At Loss |
| 2024-06-24 | At Loss | 2024-04-18 | At Loss |
| 2024-06-21 | At Loss | 2024-04-17 | At Loss |
| 2024-06-20 | At Loss | 2024-04-16 | At Loss |
| 2024-06-18 | At Loss | 2024-04-15 | At Loss |
| 2024-06-17 | At Loss | 2024-04-12 | At Loss |
| 2024-06-14 | At Loss | 2024-04-11 | At Loss |
| 2024-06-13 | At Loss | 2024-04-10 | At Loss |
| 2024-06-12 | At Loss | 2024-04-09 | At Loss |
| 2024-06-11 | At Loss | 2024-04-08 | At Loss |
| 2024-06-10 | At Loss | 2024-04-05 | At Loss |
| 2024-06-07 | At Loss | 2024-04-04 | At Loss |
| 2024-06-06 | At Loss | 2024-04-03 | At Loss |
| 2024-06-05 | At Loss | 2024-04-02 | At Loss |
| 2024-06-04 | At Loss | 2024-04-01 | At Loss |
| 2024-06-03 | At Loss | 2024-03-28 | At Loss |
| 2024-05-31 | At Loss | 2024-03-27 | At Loss |
| 2024-05-30 | At Loss | 2024-03-26 | At Loss |
| 2024-05-29 | At Loss | 2024-03-25 | At Loss |
| 2024-05-28 | At Loss | 2024-03-22 | At Loss |
| 2024-05-24 | At Loss | 2024-03-21 | At Loss |
| 2024-05-23 | At Loss | 2024-03-20 | At Loss |
| 2024-05-22 | At Loss | 2024-03-19 | At Loss |
| 2024-05-21 | At Loss | 2024-03-18 | At Loss |
| 2024-05-20 | At Loss | 2024-03-15 | At Loss |
| 2024-05-17 | At Loss | 2024-03-14 | At Loss |
| 2024-05-16 | At Loss | 2024-03-13 | At Loss |
| 2024-05-15 | At Loss | 2024-03-12 | At Loss |
| 2024-05-14 | At Loss | 2024-03-11 | At Loss |
| 2024-05-13 | At Loss | 2024-03-08 | At Loss |
| 2024-05-10 | At Loss | 2024-03-07 | At Loss |
| 2024-05-09 | At Loss | 2024-03-06 | At Loss |
| 2024-05-08 | At Loss | 2024-03-05 | At Loss |
| 2024-05-07 | At Loss | 2024-03-04 | At Loss |
| 2024-05-06 | At Loss | 2024-03-01 | At Loss |
| 2024-05-03 | At Loss | 2024-02-29 | At Loss |
| 2024-05-02 | At Loss | 2024-02-28 | At Loss |
| 2024-05-01 | At Loss | 2024-02-27 | At Loss |
| 2024-04-30 | At Loss | 2024-02-26 | At Loss |
| 2024-04-29 | At Loss | 2024-02-23 | At Loss |
| 2024-04-26 | At Loss | 2024-02-22 | At Loss |
| 2024-04-25 | At Loss | 2024-02-21 | At Loss |
| 2024-04-24 | At Loss | 2024-02-20 | At Loss |
| 2024-04-23 | At Loss | 2024-02-16 | At Loss |
| 2024-04-22 | At Loss | 2024-02-15 | At Loss |
Yubo International Biotech Ltd (YBGJ) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Yubo International Biotech Ltd
NAICS : 334517
SIC : 3841
ISIN : US9883661004
Share Class Description:
YBGJ: Ordinary Shares - Class ADescription
Yubo International Biotech Ltd is a technology company focused on the research and development and application of endometrial stem cells. It offers products and services under the brand VIVCELL. Its product offerings include healthcare products for the respiratory system, skincare products, hair care products, healthy beverages, and male and female personal care products. It also offers stem cell-related services including cell testing and health management consulting services. The company derives its revenue from the sale of certain health management services and the sale of nebulizers containing frozen tubes with medical fluid. The nebulizers are sold directly to consumers on its online e-commerce platform.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers